Search

Displaying results 961 - 970 of 1723 in total
  1. Drug

    Diphenoxylate

    go.drugbank.com/drugs/DB01081
    ApprovedIllicitInvestigational

    This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.

  2. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.

  3. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    [A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799]

  4. Drug

    Lisinopril

    go.drugbank.com/drugs/DB00722
    ApprovedInvestigational

    [A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384]

  5. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

  6. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Fostamatinib has also been granted orphan drug status by the FDA [L2644].

  7. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]

  8. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor

  9. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.

  10. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

    Synonyms: Rubivirus rubella virus Wistar RA 27/3 whole, Rubella virus strain Wistar RA 27/3 live antigen